Pharmacogenomic-Guided Antidepressant Drug Prescribing in Cancer Patients

Completed · Not applicable

Conditions studied: Depression, Anxiety, Generalized Anxiety Disorder, Depressive Disorder, Major Depressive Disorder, Cancer

In brief

This is a prospective, randomized clinical trial to investigate the clinical impact of a preemptive pharmacogenomics strategy to guide antidepressant therapy in cancer patients. Those enrolled onto the clinical trial will be randomized to either DNA-guided choice of therapy or clinical management alone. Scores on self-reported measures of depressive and anxiety symptoms along with quality of life will be compared between cohorts.

Key facts

Study ID
NCT03674138
Run by
H. Lee Moffitt Cancer Center and Research Institute
People needed
99
Starts
2018-09-12
Expected to finish
2024-10-27
Last updated by the study team
2026-02-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.